VERU Pivots Sabizabulin to Pancreatic Cancer After Preclinical Data

Veru will take oral sabizabulin into a planned Phase 2b trial in daraxonrasib-resistant pancreatic cancer and drops its cardiovascular inflammation plan.

Andre·2 min read ID: VERU-2026-09-08-1353

TickersVERU Clinical

DeskClinical

PublishedSep 8, 2026 · 13:53 ET

AccessPro story

Veru chief executive Mitchell Steiner leads the company's oncology and cardiometabolic pipeline.

RELATED STORIES

VERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer

MORE FROM THE DESK

IMMUTEP Narrows Efti Strategy After TACTI-004 Failure, Blames Manufacturing

IMUNON Signs CRADA With National Cancer Institute for IMNN-001

EYEPOINT Details LUGANO Miss, Says Nine Patients Drove Failed Endpoint

BRIDGEBIO Says Oral Infigratinib Cut Ear Infections, Stabilized Sleep Apnea